1/5 There has been a major shift in how we treat IgA nephropathy. New studies have shown that kidney failure risk begins at lower levels of proteinuria than previously appreciated, and multiple trials have demonstrated that targeted therapies can reduce the risk of progression.
Why does your IgA nephropathy care depend on who you see? In a Manitoba study published in #ASNKidney360, doctors drove 31% of variability in biopsy timing and 7% in steroid use. kidney.pub/KID1232 Bryce Barr